SG10201606218WA - Purified Proteins - Google Patents
Purified ProteinsInfo
- Publication number
- SG10201606218WA SG10201606218WA SG10201606218WA SG10201606218WA SG10201606218WA SG 10201606218W A SG10201606218W A SG 10201606218WA SG 10201606218W A SG10201606218W A SG 10201606218WA SG 10201606218W A SG10201606218W A SG 10201606218WA SG 10201606218W A SG10201606218W A SG 10201606218WA
- Authority
- SG
- Singapore
- Prior art keywords
- purified proteins
- proteins
- purified
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
- B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
- B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
- B01D15/362—Cation-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
- B01D15/3847—Multimodal interactions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Analytical Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161513453P | 2011-07-29 | 2011-07-29 | |
| US201261591727P | 2012-01-27 | 2012-01-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201606218WA true SG10201606218WA (en) | 2016-09-29 |
Family
ID=46682907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201606218WA SG10201606218WA (en) | 2011-07-29 | 2012-07-27 | Purified Proteins |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20140341843A1 (en) |
| EP (1) | EP2736524A1 (en) |
| JP (1) | JP2014522868A (en) |
| CN (1) | CN104066439A (en) |
| AU (1) | AU2012290379A1 (en) |
| BR (1) | BR112014002173A2 (en) |
| CA (1) | CA2843197A1 (en) |
| RU (1) | RU2014107743A (en) |
| SG (1) | SG10201606218WA (en) |
| WO (1) | WO2013019652A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2806438C (en) | 2010-07-29 | 2021-04-13 | Eleven Biotherapeutics, Inc. | Chimeric il-1 receptor type i agonists and antagonists |
| JP6450364B2 (en) * | 2013-03-13 | 2019-01-09 | セセン バイオ, インコーポレイテッド | Chimeric cytokine formulations for ocular delivery |
| AU2013203043B2 (en) | 2013-03-15 | 2016-10-06 | Takeda Pharmaceutical Company Limited | Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs |
| PT3461891T (en) * | 2014-01-24 | 2020-07-30 | Am Pharma Bv | Downstream processing of an alkaline phosphatase |
| TW201538178A (en) * | 2014-03-13 | 2015-10-16 | Eleven Biotherapeutics Inc | Methods for production of stable chimeric cytokine protein formulations in blow fill seal containers |
| CN107108711B (en) * | 2014-10-23 | 2021-11-23 | 恩格姆生物制药公司 | Pharmaceutical compositions comprising peptide variants and methods of use thereof |
| TW201702380A (en) * | 2015-02-27 | 2017-01-16 | 再生元醫藥公司 | Host cell protein modification |
| CN104710527B (en) * | 2015-02-28 | 2018-08-24 | 苏州金盟生物技术有限公司 | A kind of endotoxin removal method of biological products |
| ES3034020T3 (en) * | 2016-08-15 | 2025-08-12 | Hoffmann La Roche | Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide |
| JP2023523823A (en) | 2020-05-01 | 2023-06-07 | カシーヴ バイオサイエンシズ,リミテッド・ライアビリティ・カンパニー | Improved process of protein purification |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
| US5693489A (en) | 1984-03-30 | 1997-12-02 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
| US4770781A (en) * | 1986-03-03 | 1988-09-13 | Merck & Co., Inc. | Purification of human interleukin-1 species |
| US4883658A (en) | 1986-04-28 | 1989-11-28 | Holly Frank J | Ophthalmic solution for treatment of dry-eye syndrome |
| US4804539A (en) | 1986-07-28 | 1989-02-14 | Liposome Technology, Inc. | Ophthalmic liposomes |
| US4801686A (en) * | 1986-09-04 | 1989-01-31 | Immunex Corporation | Purification of recombinant interleukin-1 |
| US5278151A (en) | 1987-04-02 | 1994-01-11 | Ocular Research Of Boston, Inc. | Dry eye treatment solution |
| JP2799483B2 (en) * | 1988-03-09 | 1998-09-17 | 大塚製薬株式会社 | Method for stabilizing interleukin-1β composition |
| AU4005289A (en) | 1988-08-25 | 1990-03-01 | Smithkline Beecham Corporation | Recombinant saccharomyces |
| US5075104A (en) | 1989-03-31 | 1991-12-24 | Alcon Laboratories, Inc. | Ophthalmic carboxy vinyl polymer gel for dry eye syndrome |
| CA2068320C (en) * | 1989-11-29 | 2000-10-17 | Robert Hageman | Production of recombinant human interleukin-1 inhibitor |
| ZA912797B (en) | 1990-05-29 | 1992-12-30 | Boston Ocular Res | Dry eye treatment process and solution |
| FI951250A0 (en) * | 1992-09-17 | 1995-03-16 | Synergen Inc | Pharmaceutical formulations of interleukin-1 inhibitors |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| JP2000512143A (en) * | 1996-06-07 | 2000-09-19 | グルポ・レペチツト・エス・ピー・エイ | Method for purifying human interleukin 1 receptor antagonist from recombinant Escherichia coli |
| WO1998024477A1 (en) * | 1996-12-06 | 1998-06-11 | Amgen Inc. | Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases |
| ES2649037T3 (en) | 2000-12-12 | 2018-01-09 | Medimmune, Llc | Molecules with prolonged half-lives, compositions and uses thereof |
| CA2557910C (en) * | 2004-04-02 | 2012-05-29 | Amgen Inc. | Methods of reducing aggregation of il-1ra |
| WO2005021578A2 (en) * | 2004-08-25 | 2005-03-10 | Amprotein Corporation | A novel chimeric polypeptide and use thereof |
| RU2007119989A (en) * | 2004-12-02 | 2009-01-10 | Домантис Лимитед (Gb) | COMPOSITIONS, FUSED CONSTRUCTIONS AND PLAD DOMAIN CONJUGATES |
| ES2362386T3 (en) | 2007-06-21 | 2011-07-04 | Technische Universität München | ACTIVE BIOLOGICAL PROTEINS THAT HAVE INCREASED STABILITY IN VIVO AND / OR IN VITRO. |
| BRPI0815416A2 (en) | 2007-08-15 | 2014-10-21 | Amunix Inc | COMPOSITIONS AND METHODS FOR MODIFYING PROPERTIES OF BIOLOGICALLY ACTIVE POLYPEPTIDES |
| WO2011063195A2 (en) * | 2009-11-20 | 2011-05-26 | Dr. Reddy's Laboratories Ltd. | Purification of modified cytokines |
| CA2806438C (en) * | 2010-07-29 | 2021-04-13 | Eleven Biotherapeutics, Inc. | Chimeric il-1 receptor type i agonists and antagonists |
| WO2012103240A2 (en) * | 2011-01-25 | 2012-08-02 | Eleven Biotherapeutics, Inc. | Receptor binding agents |
-
2012
- 2012-07-27 AU AU2012290379A patent/AU2012290379A1/en not_active Abandoned
- 2012-07-27 CA CA2843197A patent/CA2843197A1/en not_active Abandoned
- 2012-07-27 JP JP2014523080A patent/JP2014522868A/en active Pending
- 2012-07-27 RU RU2014107743/10A patent/RU2014107743A/en not_active Application Discontinuation
- 2012-07-27 BR BR112014002173A patent/BR112014002173A2/en not_active IP Right Cessation
- 2012-07-27 SG SG10201606218WA patent/SG10201606218WA/en unknown
- 2012-07-27 US US14/235,777 patent/US20140341843A1/en not_active Abandoned
- 2012-07-27 EP EP12748087.9A patent/EP2736524A1/en not_active Withdrawn
- 2012-07-27 WO PCT/US2012/048631 patent/WO2013019652A1/en not_active Ceased
- 2012-07-27 CN CN201280046036.2A patent/CN104066439A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013019652A1 (en) | 2013-02-07 |
| CA2843197A1 (en) | 2013-02-07 |
| JP2014522868A (en) | 2014-09-08 |
| BR112014002173A2 (en) | 2017-03-01 |
| AU2012290379A1 (en) | 2014-02-06 |
| RU2014107743A (en) | 2015-09-10 |
| EP2736524A1 (en) | 2014-06-04 |
| CN104066439A (en) | 2014-09-24 |
| US20140341843A1 (en) | 2014-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL228438A0 (en) | Novel protein purification methods | |
| GB201012603D0 (en) | Protein purification | |
| EP2673635A4 (en) | Apoe immunotherapy | |
| GB201113811D0 (en) | Protein recovery | |
| EP2719500A4 (en) | Workpiece-processing system | |
| ZA201401140B (en) | Polypeptide separation methods | |
| SG10201606218WA (en) | Purified Proteins | |
| GB201111183D0 (en) | Peptide | |
| GB2491044B (en) | Ablutionary system | |
| EP2663331A4 (en) | Novel uses | |
| GB201115910D0 (en) | Peptides | |
| GB201119167D0 (en) | Novel bachteriophages | |
| EP2773959A4 (en) | PROTEIN FRACTIONATION BASED ON pI | |
| PL2741811T3 (en) | Symptom-treatment system | |
| GB201107468D0 (en) | Protein expression systems | |
| EP2716258A4 (en) | Intrastomal segment | |
| EP2700820A4 (en) | Motor-securing system | |
| GB201101794D0 (en) | Protein production | |
| HUP1100282A2 (en) | Protein factor | |
| GB201103169D0 (en) | Protein expression | |
| GB201115014D0 (en) | Peptides | |
| GB201106130D0 (en) | Polypeptide | |
| GB201112849D0 (en) | Polypeptide | |
| GB201112985D0 (en) | Polypeptide | |
| GB201111218D0 (en) | Sequence |